v3.26.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2026
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

Item 5. Other Information.

Director and Officer Trading Arrangements

 

The following table describes, for the period covered by this Quarterly Report, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”). For the period covered by this Quarterly Report, none of our directors or officers adopted or terminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).

 

Name

Title

Action Taken

Date

Shares to be Sold

Expiration Date

Douglas Kerr, M.D.

Chief Medical Officer

Adopted

March 18, 2026

34,652*

June 17, 2027

 

* In addition to 10% of the number of shares acquired upon the vesting of restricted stock units after a sell-to-cover transaction to satisfy tax withholding obligations, which number cannot be determined at this time.
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Douglas Kerr [Member]  
Trading Arrangements, by Individual  
Name Douglas Kerr, M.D.
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 18, 2026
Expiration Date June 17, 2027
Aggregate Available 34,652 [1]
[1] In addition to 10% of the number of shares acquired upon the vesting of restricted stock units after a sell-to-cover transaction to satisfy tax withholding obligations, which number cannot be determined at this time.